超级碰在线-超级碰碰永久免费视频播放-超级碰碰碰免费视频播放-超级碰碰碰免费视频-亚洲国产99在线精品一区69堂-亚洲高清资源在线观看

泰和誠(chéng)醫(yī)療,concord medical,  
泰和誠(chéng)是一家專業(yè)的醫(yī)療服務(wù)公司，擁有目前中國(guó)最大的腫瘤放射治療和影像診斷網(wǎng)絡(luò)。自成立以來(lái)，泰和誠(chéng)一直致力于向中國(guó)醫(yī)療領(lǐng)域引進(jìn)國(guó)際高科技大型醫(yī)療診斷治療設(shè)備，尤其是世界上技術(shù)最前沿的腫瘤診斷與放射治療設(shè)備，努力為腫瘤患者提供先進(jìn)而有效的診療手段和優(yōu)質(zhì)的醫(yī)療服務(wù)。時(shí)至今日，泰和誠(chéng)的腫瘤醫(yī)療服務(wù)網(wǎng)絡(luò)已經(jīng)覆蓋了中國(guó)20多個(gè)省市的逾35個(gè)主要城市，并繼續(xù)在更多的地區(qū)積極拓展相關(guān)的業(yè)務(wù)。

通過(guò)租賃和提供專業(yè)管理的方式，泰和誠(chéng)在中國(guó)許多醫(yī)院都建立了腫瘤診療中心。通常每個(gè)中心都配備一套先進(jìn)而昂貴的放射治療和影像診斷設(shè)備，如醫(yī)用加速器（包括高端的直線加速器和回旋加速器）、頭部伽瑪?shù)断到y(tǒng)、體部伽瑪?shù)断到y(tǒng)、正電子發(fā)射計(jì)算機(jī)斷層影像掃描系統(tǒng)或磁共振成像系統(tǒng)。公司向網(wǎng)絡(luò)各中心的醫(yī)生提供醫(yī)療支持服務(wù)，如組織醫(yī)生會(huì)診和醫(yī)學(xué)研究等。

為進(jìn)一步增強(qiáng)公司的業(yè)務(wù)發(fā)展，提高公司的聲譽(yù)，泰和誠(chéng)投資的兩家腫瘤專科醫(yī)院（包括長(zhǎng)安泰和國(guó)際腫瘤中心和北京質(zhì)子中心）正在建設(shè)之中，將集中目前國(guó)際上最先進(jìn)的設(shè)備與技術(shù)，為腫瘤患者提供更加豐富的診療手段和更加細(xì)分化的服務(wù)。

據(jù)統(tǒng)計(jì)，在2008年，癌癥是中國(guó)居民死亡的首要病因。而與發(fā)達(dá)國(guó)家相比，中國(guó)國(guó)內(nèi)的放射治療和影像診斷設(shè)備的普及率卻很低。根據(jù)Frost & Sullivan提供的最新數(shù)據(jù), 2008年至2015年間，中國(guó)放射治療和影像診斷市場(chǎng)的復(fù)合年均增長(zhǎng)率預(yù)計(jì)將達(dá)22.4%。增長(zhǎng)的主要驅(qū)動(dòng)因素包括中國(guó)癌癥發(fā)病率的不斷增長(zhǎng), 醫(yī)生和患者對(duì)癌癥的認(rèn)知度越來(lái)越高，以及醫(yī)院采用先進(jìn)的放射治療和影像診斷技術(shù)。同時(shí)，家庭可支配收入和政府醫(yī)療保健支出的不斷增長(zhǎng)也將進(jìn)一步提高人們對(duì)癌癥治療和診斷費(fèi)用的支付能力。

泰和誠(chéng)分布在全國(guó)的龐大網(wǎng)絡(luò)、在腫瘤放射治療和影像診斷領(lǐng)域的豐富經(jīng)驗(yàn)，以及業(yè)內(nèi)領(lǐng)先的專家團(tuán)隊(duì)使我們能夠不斷滿足中國(guó)放射治療和影像診斷服務(wù)市場(chǎng)的迫切需要和不斷推動(dòng)行業(yè)的健康發(fā)展。

CMS partners with hospitals to build radiotherapy and diagnostic imaging centers. Each center is typically equipped with a primary unit of advanced radiotherapy and diagnostic imaging equipment, such as linear accelerators, head gamma knife systems, body gamma knife systems, positron emission tomography-computed tomography (PET-CT) scanners or magnetic resonance imaging (MRI) scanners. The Company provides clinical support services to doctors working in the centers in its network, such as organizing joint diagnosis among doctors in its network and clinical research, while its hospital partners are responsible for the centers' clinical activities, doctors' medical decisions and the employment of the doctors.

Concord Medical Services Holdings Limited ("CMS" or "the Company") operates China's largest network in terms of revenue and total number of centers in operation in 2008. Since its inception CMS has been committed to building an extensive network of radiotherapy and diagnostic imaging centers in China and employing state-of-the art medical technology to sustain lives and reduce sufferings. Today, the Company operates a network of more than 80 centers spanning more than 35 cities and 20 provinces and administrative regions in China.

To further enhance its reputation and to employ high quality doctors, the Company plans to establish and operate specialty cancer hospitals in China. Its first specialty cancer hospital, the Chang'an CMS International Cancer Center, in Xi'an, Shaanxi Province, is expected to be operational in early 2010. The Company is also in the process of establishing the Beijing Proton Medical Center, which is expected to commence operations in 2012.

Cancer was the leading cause of death in China in 2008, yet there is a relatively low penetration rate of radiotherapy and diagnostic imaging equipment compared to developed countries. According to Frost & Sullivan, the radiotherapy and diagnostic imaging market in China is expected to grow at a CAGR of 22.4% between 2008 and 2015. Growth drivers include increasing cancer rates in China, growing awareness among physicians and patients and hospitals' adoption of advanced radiotherapy and diagnostic imaging technologies. Furthermore, rising household disposable income and government healthcare expenditures will increase the affordability of such cancer treatment and diagnosis technologies.

With its leading network and its experience and expertise, the Company is uniquely positioned to address the underserved radiotherapy and diagnostic imaging services market in China.